Corbus (CRBP) CFO receives 28,082 RSUs and 84,247 stock options grants

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean F. Moran. On January 14, 2026, he received 28,082 restricted stock units (RSUs) that will settle in common stock. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a pro rata acceleration feature if the company terminates his service without cause after the first vesting date. Following this grant, he beneficially owns 101,395 shares of common stock, including 85,714 unvested RSUs.

On the same date, he was also granted stock options to purchase 84,247 shares of common stock at an exercise price of $8.26 per share, expiring January 14, 2036. Under the company’s 2024 Equity Compensation Plan, 25% of this option vests on January 14, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Sean F.

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	01/14/2026		A		28,082(1)	A	$0	101,395(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$8.26	01/14/2026		A		84,247		(3)	01/14/2036	Common Stock	84,247	$0	84,247	D

Explanation of Responses:

1. On January 14, 2026, the Reporting Person was granted 28,082 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

2. This amount includes 85,714 unvested RSUs subject to each grant's vesting schedule as previously reported.

3. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

	/s/Sean Moran	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corbus Pharmaceuticals (CRBP) report in this Form 4?

The filing reports equity compensation grants to Chief Financial Officer Sean F. Moran, including new restricted stock units and stock options awarded on January 14, 2026.

How many RSUs were granted to the Corbus (CRBP) CFO and how do they vest?

The CFO received 28,082 RSUs, which will be settled in common stock. 25% vest on each of the first, second, third and fourth anniversaries beginning on January 14, 2027, subject to the terms described.

Is there any accelerated vesting feature for the Corbus CFO’s RSUs?

Yes. If the company terminates the CFO’s service without cause after the first vesting date, a pro rata portion of the RSUs scheduled to vest on the next vesting date will accelerate based on completed months of service, and unaccelerated RSUs will be forfeited.

How many stock options did the Corbus (CRBP) CFO receive and at what exercise price?

He was granted 84,247 stock options with an exercise price of $8.26 per share, each option representing the right to buy one share of common stock.

What is the vesting schedule for the Corbus CFO’s new stock options?

Under the 2024 Equity Compensation Plan, 25% of the option vests on January 14, 2027. The remaining 75% vests in equal monthly installments over 36 months starting February 14, 2027.

How many Corbus common shares does the CFO beneficially own after these grants?

Following the reported RSU grant, the CFO beneficially owns 101,395 shares of common stock, which includes 85,714 unvested RSUs subject to their respective vesting schedules.

When do the Corbus CFO’s new stock options expire?

The stock options granted on January 14, 2026 are scheduled to expire on January 14, 2036, subject to plan and award terms.